Targets › SLC23A2
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Mar 2028.
Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate. (UniProt, Q9UGH3)
Open in Phaseline: the race on SLC23A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UroGen Pharma | UGN-102 Mitomycin-hydrogel intravesical solution; mitomycin is a DNA alkylating agent | SLC23A2 | Phase 3 | Bladder Cancer | Mar 2028 |
Bladder Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.